CD160 and non-Hodgkin lymphoma: In our study, 100% of patients with CLL had positive CD200 expression on B-cell by percentage versus 56% B-NHL and 100% HCL, while 50% of patients with CLL had CD160 B-cell by MFI ratio versus 24% B-NHL and 60% HCL.